CUE, US22978P2056

Cue Biopharma stock last stood at USD 16.71 on October 16 before earnings

Published on 10/17/2026 at 18:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 7.88 million in the second quarter. Cue Biopharma stock stood at USD 16.71 on October 16, 2026, down 10.50 percent.

Earnings date and valuation

Cue Biopharma's next earnings report is scheduled for November 12, 2026.
Revenue reached USD 7.88 million in the second quarter of 2026.
Cue Biopharma stock stood at USD 16.71 on October 16, 2026, down 10.50 percent versus the Nasdaq prior close.
The market capitalization was USD 121.4 million on October 16, 2026.

CUE, US22978P2056, Illustration mit AI erstellt.

Cue Biopharma's next earnings report is scheduled for November 12, 2026, according to Investing.com. The date gives investors the next fixed point after a sharp decline in the latest completed Nasdaq session. Cue Biopharma stock last stood at USD 16.71 on October 16, 2026, down 10.50 percent versus the Nasdaq prior close of USD 18.67.

Revenue exceeded estimates

Cue Biopharma reported USD 7.88 million in revenue for the second quarter of 2026, compared with a USD 3.00 million consensus estimate, according to MarketBeat. The same report said adjusted earnings per share were a loss of USD 24.14, versus a consensus loss of USD 1.69. Revenue therefore provided the stronger reported comparison, while the earnings figure showed the cost of the company's clinical-stage development model.

Stock remains below its high

The Nasdaq-listed biotechnology company traded within a 52-week range of USD 4.97 to USD 45.50 on October 16, 2026. Its last price was 63.32 percent below the 52-week high, calculated from the same quoted values. The session volume was 105,195 shares, against an average volume of 272,406 shares.

Cue Biopharma's market capitalization was USD 121.4 million on October 16, 2026, while its price-to-earnings ratio was negative 0.62. The company paid no dividend yield in the quoted market data. Its pipeline centers on immune-focused therapies, including CUE-221, an anti-IgE antibody advancing toward later-stage study, according to the company's investor-relations page.

Comparison with peers

Cue Biopharma (Nasdaq, USD): minus 10.50 percent, P/E -0.62, market capitalization USD 121.4 million
Immunic (Nasdaq, USD): minus 1.83 percent, P/E -1.45, market capitalization USD 95.1 million
Chimerix (Nasdaq, USD): 0.00 percent, P/E -8.63, market capitalization USD 801.1 million

What comes next

The November 12, 2026 earnings date is the next scheduled corporate event cited by Investing.com. The report should put the USD 7.88 million second-quarter revenue figure, the USD 24.14 earnings-per-share loss and cash usage into a fresh reporting-period context.

Price and reporting date

The next report date and the latest financial comparison frame the stock's current position. The company had a market capitalization of USD 121.4 million on October 16, 2026, and its price remained well below the USD 45.50 52-week high.